During this fireside chat we welcome InMed Pharmaceuticals, ticker symbol of INM on the NASDAQ. And joining us is Eric Adams, the company’s Chief Executive Officer; and Chris Meiering, the company’s Vice President Commercial Operations. InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs.

This Fireside Chat was recorded during the Lytham Partners Winter 2021 Investor Conference.